US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veradermics, Inc.

98.97

+0.83000.85%

Post-market: 99.500.5300+0.54%19:59 EDT

Volume:576.03K

Turnover:57.52M

Market Cap:4.13B

PE:-15.36

High:102.29

Open:99.45

Low:98.82

Close:98.14

52wk High:131.24

52wk Low:32.00

Shares:41.78M

Float Shares:32.29M

Volume Ratio:1.21

T/O Rate:1.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.4439

EPS(LYR):-111.9114

ROE:-72.06%

ROA:-43.45%

PB:5.08

PE(LYR):-0.88

Loading ...

Overview Company News Filings

BUZZ-Veradermics jumps after experimental oral hair loss pill posts positive late‑stage trial results

Veradermics Shares Gain on Positive Data from Hair Loss Treatment Study

A new version of an old drug is helping men grow back some of their hair

Veradermics Inc - Vdphl01 Shows Favorable Safety Profile With Adverse Event Rates Similar to Placebo

THOMSON REUTERS

Veradermics Inc - Vdphl01 Meets All Primary and Key Secondary Endpoints With High Statistical Significance

THOMSON REUTERS

Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss

THOMSON REUTERS

Veradermics to report Phase 2/3 VDPHL01 trial topline results in male hair loss

Veradermics to Hold Conference Call to Discuss Topline Results From Phase 2/3 ‘302’ Study of Vdphl01 in Males With Mild-to-Moderate Pattern Hair Loss

THOMSON REUTERS

Veradermics Is Maintained at Outperform by Leerink Partners

Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate

Benzinga Earnings

BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results

Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M

MT Newswires Live

Veradermics reports Q4 net loss $21.8M vs $5.7M last year

Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million

Veradermics Inc - Q4 Net Loss $21.8 Mln

THOMSON REUTERS

Press Release: Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Veradermics management to meet with Jefferies

Senior Living REIT IPO Shows Wall Street Remains Hot for Yield Plays -- Barrons.com

Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/MANE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MANE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","market":"US","secType":"STK","nameCN":"Veradermics, Inc.","latestPrice":98.97,"timestamp":1789156800000,"preClose":98.14,"halted":0,"volume":576027,"hourTrading":{"tag":"盘后","latestPrice":99.5,"preClose":98.97,"latestTime":"19:59 EDT","volume":3719,"amount":368536.649,"timestamp":1789171175914,"change":0.53,"changeRate":0.005355,"amplitude":0.005355},"delay":0,"changeRate":0.00845730588954553,"floatShares":32290700,"shares":41778687,"eps":-6.443948,"marketStatus":"Market Closed","change":0.83,"latestTime":"09-11 16:00:00 EDT","open":99.45,"high":102.29,"low":98.815,"amount":57520829.28249,"amplitude":0.035409,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.443948,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1770181200000,"exchange":"NYSE","adjPreClose":98.14,"preHourTrading":{"tag":"盘前","latestPrice":101.97,"preClose":98.14,"latestTime":"09:27 EDT","volume":23,"amount":2263.98039,"timestamp":1789133271809,"change":3.83,"changeRate":0.039026,"amplitude":0.036275},"postHourTrading":{"tag":"盘后","latestPrice":99.5,"preClose":98.97,"latestTime":"19:59 EDT","volume":3719,"amount":368536.649,"timestamp":1789171175914,"change":0.53,"changeRate":0.005355,"amplitude":0.005355},"volumeRatio":1.2090439806914655,"impliedVol":1.1183,"impliedVolPercentile":0.881},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","floatShares":32290700,"roa":"-43.45%","roe":"-72.06%","lyrEps":-111.911419,"volumeRatio":1.2090439806914655,"shares":41778687,"dividePrice":0,"high":102.29,"amplitude":0.035409,"preClose":98.14,"low":98.815,"week52Low":32,"pbRate":"5.08","week52High":131.2399,"institutionHeld":0,"latestPrice":98.97,"eps":-6.443948,"divideRate":0,"volume":576027,"delay":0,"ttmEps":-6.443948,"open":99.45,"prevYearClose":17,"prevWeekClose":98.51,"prevMonthClose":98.41,"prevQuarterClose":122.94,"fiveDayClose":97.75,"twentyDayClose":111,"sixtyDayClose":90.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MANE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MANE","fiscalQuarterEnding":"2026/06","expectedEps":-0.58,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MANE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MANE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1784174400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MANE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MANE","date":"2026-09-11","current":-15.358597,"percent":0.615894,"low":-67.545361,"twenty":-54.067463,"median":-46.421397,"eighty":-34.344005,"high":-9.296992,"avg":-45.273661,"sd":10.715026,"marketCap":4100302547},"quantilePoints":[{"date":"2026-02-06","current":-25.786263,"twenty":-25.079893,"median":-17.8457,"eighty":-10.368249,"marketCap":1387507243},{"date":"2026-02-13","current":-30.838039,"twenty":-29.065754,"median":-25.786263,"eighty":-19.198356,"marketCap":1659333205},{"date":"2026-02-20","current":-33.530469,"twenty":-32.062123,"median":-28.069277,"eighty":-25.043809,"marketCap":1804207481},{"date":"2026-02-27","current":-29.776333,"twenty":-31.085076,"median":-29.967163,"eighty":-25.732137,"marketCap":1602204947},{"date":"2026-03-06","current":-33.738647,"twenty":-32.654736,"median":-30.560469,"eighty":-26.152655,"marketCap":1815409101},{"date":"2026-03-13","current":-35.785726,"twenty":-33.721993,"median":-31.049686,"eighty":-27.249057,"marketCap":1925558357},{"date":"2026-03-20","current":-39.491287,"twenty":-35.53175,"median":-31.816474,"eighty":-28.546698,"marketCap":2124947181},{"date":"2026-03-27","current":-46.874652,"twenty":-39.507941,"median":-32.867771,"eighty":-29.468231,"marketCap":2522231279},{"date":"2026-04-02","current":-31.356106,"twenty":-39.513493,"median":-32.867771,"eighty":-29.852665,"marketCap":2194770608},{"date":"2026-04-10","current":-31.99758,"twenty":-38.92088,"median":-32.857362,"eighty":-30.17702,"marketCap":2239670594},{"date":"2026-04-17","current":-39.540857,"twenty":-39.536494,"median":-33.608872,"eighty":-30.279902,"marketCap":2767662294},{"date":"2026-04-24","current":-36.942854,"twenty":-39.536494,"median":-33.738647,"eighty":-30.421684,"marketCap":2585815082},{"date":"2026-05-01","current":-52.813611,"twenty":-40.831905,"median":-34.49692,"eighty":-30.615983,"marketCap":3696688710},{"date":"2026-05-08","current":-63.45616,"twenty":-42.963163,"median":-35.411007,"eighty":-30.844978,"marketCap":4441613943},{"date":"2026-05-15","current":-51.496667,"twenty":-46.59847,"median":-35.988193,"eighty":-30.890717,"marketCap":4368307751},{"date":"2026-05-22","current":-50.831536,"twenty":-50.412067,"median":-36.702792,"eighty":-31.015444,"marketCap":4311886693},{"date":"2026-05-29","current":-50.670085,"twenty":-50.670085,"median":-37.508333,"eighty":-31.226637,"marketCap":4298191318},{"date":"2026-06-05","current":-49.857433,"twenty":-50.482929,"median":-39.295461,"eighty":-31.282151,"marketCap":4229256485},{"date":"2026-06-12","current":-46.493546,"twenty":-50.049515,"median":-39.519044,"eighty":-31.356106,"marketCap":3943908052},{"date":"2026-06-18","current":-45.24748,"twenty":-50.006173,"median":-40.004977,"eighty":-31.7244,"marketCap":3838207974},{"date":"2026-06-26","current":-58.79168,"twenty":-50.634624,"median":-40.906894,"eighty":-31.961359,"marketCap":4987121867},{"date":"2026-07-02","current":-63.278505,"twenty":-51.067836,"median":-42.661209,"eighty":-32.20951,"marketCap":5367725705},{"date":"2026-07-10","current":-61.520221,"twenty":-53.048338,"median":-44.057315,"eighty":-32.416525,"marketCap":5218575793},{"date":"2026-07-17","current":-52.123009,"twenty":-54.2625,"median":-44.976596,"eighty":-32.698555,"marketCap":4421438445},{"date":"2026-07-24","current":-57.062948,"twenty":-54.490042,"median":-45.472923,"eighty":-32.869852,"marketCap":4840478675},{"date":"2026-07-31","current":-51.531989,"twenty":-54.856474,"median":-45.794173,"eighty":-33.139095,"marketCap":4371304020},{"date":"2026-08-07","current":-53.511905,"twenty":-54.832834,"median":-46.684099,"eighty":-33.593192,"marketCap":4539254342},{"date":"2026-08-14","current":-50.036631,"twenty":-54.832834,"median":-47.316049,"eighty":-33.69117,"marketCap":4637595096},{"date":"2026-08-21","current":-47.476198,"twenty":-54.602336,"median":-47.561116,"eighty":-33.713665,"marketCap":4400283923},{"date":"2026-08-28","current":-45.893958,"twenty":-54.263485,"median":-47.316049,"eighty":-33.861631,"marketCap":4253635646},{"date":"2026-09-04","current":-44.06379,"twenty":-54.197488,"median":-46.684099,"eighty":-34.12449,"marketCap":4084008294},{"date":"2026-09-11","current":-44.239594,"twenty":-54.067463,"median":-46.421397,"eighty":-34.344005,"marketCap":4100302547}],"updateTime":1789243454799},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MANE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630395018","title":"BUZZ-Veradermics jumps after experimental oral hair loss pill posts positive late‑stage trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395018?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:53","pubTimestamp":1777290827,"startTime":"0","endTime":"0","summary":"BUZZ-Veradermics jumps after experimental oral hair loss pill posts positive latestage trial results** Shares of biotech firm Veradermics MANE.N jump 25% to $84.84 premarket** Co says it reported positive latestage trial results for its experimental oral drug for pattern hair loss** Says its pill VDPHL01 targets male pattern hair loss, a common condition in which men gradually lose scalp hair due to genetics and hormones** Says the sixmonth study in more than 500 men showed patients on the drug gained over 30 hairs per square cm versus seven on placebo** Adds that nearly 80% of patients on VDPHL01 reported improvement, compared with about 36% on placebo, with benefits seen as early as two months** Says the pill is a nonhormonal, extendedrelease version of minoxidil and showed no serious heartrelated safety issues** Says it plans further studies, including trials in women, with more results expected in 2026** As of last close, stock flat YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL4N41A11O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630539541","title":"Veradermics Shares Gain on Positive Data from Hair Loss Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2630539541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630539541?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:45","pubTimestamp":1777290300,"startTime":"0","endTime":"0","summary":"Shares of Veradermics climbed after the company shared what it called positive data from a recent trial of its in-development therapy for pattern hair loss.The stock rose 16%, to $79.01, in premarket trading Monday. The stock had its public debut in February, with Veradermics pricing its initial offering of 15.1 million shares at $17 apiece.The biopharmaceutical company said data from a Phase 2/3 clinical trial of the drug, VDPHL01, positions it to become the first Food and Drug Administration-approved oral pill in nearly 30 years for pattern hair loss, as well as a potential best-in-indication treatment option.The recent trial of the treatment met all primary and all key secondary endpoints with statistical significance, demonstrating robust increases in hair count while being generally well tolerated, Veradermics said.Nearly 80% of patients in the once-daily dose arm and 86% of patients in the twice-daily dose arm reported improvement in hair coverage after six months of treatment wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630739824","title":"A new version of an old drug is helping men grow back some of their hair","url":"https://stock-news.laohu8.com/highlight/detail?id=2630739824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630739824?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:03","pubTimestamp":1777287780,"startTime":"0","endTime":"0","summary":"Veradermics is developing an extended-release version of oral minoxidil. Veradermics is testing an extended-release formulation of oral minoxidil  in clinical trials.A safer - and more effective - formulation of a popular hair-loss treatment led to robust hair growth in a later-stage clinical trial.Veradermics is working on an extended-release version of oral minoxidil that is thought to reduce the heart palpitations and low blood pressure that can occur when people take higher doses of a minoxidil pill. Minoxidil has the same ingredient as Rogaine, which is available topically over the counter. It's also often prescribed off-label as a pill but can't be taken orally in high doses because of those cardiovascular risks.This is where Veradermics comes in. On Monday, the company announced the first batch of late-stage data that showed solid results for its extended-release minoxidil pill. Veradermics' stock  rallied 16.9% in premarket trade.There is another drug called finasteride that wo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630228398","title":"Veradermics Inc - Vdphl01 Shows Favorable Safety Profile With Adverse Event Rates Similar to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2630228398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630228398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630215398","title":"Veradermics Inc - Vdphl01 Meets All Primary and Key Secondary Endpoints With High Statistical Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2630215398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630215398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630039895","title":"Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630039895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630039895?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336733","title":"Veradermics to report Phase 2/3 VDPHL01 trial topline results in male hair loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336733","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630336733?lang=en_us&edition=fundamental","pubTime":"2026-04-27 04:00","pubTimestamp":1777233624,"startTime":"0","endTime":"0","summary":"Veradermics scheduled investor call and webcast for April 27, 2026, to present topline results from Part A of Phase 2/3 ‘302’ trial of VDPHL01 in males with mild-to-moderate pattern hair loss.Update will cover initial readout from randomized, double-blind, placebo-controlled study of extended-release oral minoxidil tablet.Presentation timing signals near-term catalyst for program positioning ahead of potential late-stage development and commercialization planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on April 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nNDL9Rnkw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630833673","title":"Veradermics to Hold Conference Call to Discuss Topline Results From Phase 2/3 ‘302’ Study of Vdphl01 in Males With Mild-to-Moderate Pattern Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630833673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630833673?lang=en_us&edition=fundamental","pubTime":"2026-04-27 04:00","pubTimestamp":1777233601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUA6HXHK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629331040","title":"Veradermics Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2629331040","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629331040?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:19","pubTimestamp":1776867540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MANE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 10:19 ET (14:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623451533","title":"Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623451533","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623451533?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:45","pubTimestamp":1774878312,"startTime":"0","endTime":"0","summary":"Veradermics (NYSE:MANE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51538413/veradermics-q4-eps-0-62-beats-0-66-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623777312","title":"BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623777312","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623777312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:02","pubTimestamp":1774872120,"startTime":"0","endTime":"0","summary":"BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results March 30 (Reuters) - Veradermics Inc MANE.N:VERADERMICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND HI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA8GDFWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370312","title":"Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370312","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:44","pubTimestamp":1774871093,"startTime":"0","endTime":"0","summary":"Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312847","title":"Veradermics reports Q4 net loss $21.8M vs $5.7M last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312847?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:36","pubTimestamp":1774870611,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025. “2025 was a landmark year for Veradermics (MANE),...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q4-net-loss-21-8m-vs-5-7m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q4-net-loss-21-8m-vs-5-7m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623431410","title":"Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623431410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623431410?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:31","pubTimestamp":1774870312,"startTime":"0","endTime":"0","summary":"Veradermics posted a Q4 net loss of $21.8 million, widening from a year earlier.R&D expense jumped to $62.1 million, due to higher VDPHL01 clinical development spending and increased headcount.Cash, cash equivalents, and marketable securities totaled $141.9 million; an upsized IPO in February raised gross proceeds of about $295 million.Management expects cash runway into 2029, with VDPHL01 Study 302 topline data due in H1 2026 and Study 304 topline data expected in H2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL63lYDh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314763","title":"Veradermics Inc - Q4 Net Loss $21.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314763?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA8GDFWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314427","title":"Press Release: Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314427","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314427?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026. Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss. Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer. Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and the anticipated launch of VDPHL01, if approved. Veradermics, Incorporated , a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today reported financial results for the fourth quarter and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","IPO","BK4232","R","BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622709054","title":"Veradermics management to meet with Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2622709054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622709054?lang=en_us&edition=fundamental","pubTime":"2026-03-25 02:40","pubTimestamp":1774377614,"startTime":"0","endTime":"0","summary":"Dinner Meeting to be held in New York on March 24 at 6 pm hosted by Jefferies. Published first on TheFly – the ultimate source for real-time, marke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-management-to-meet-with-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-management-to-meet-with-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620302947","title":"Senior Living REIT IPO Shows Wall Street Remains Hot for Yield Plays -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2620302947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620302947?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:46","pubTimestamp":1774021560,"startTime":"0","endTime":"0","summary":"Real estate stocks have been winners in this oil- and Iran-obsessed volatile stock market. That bodes well for Janus Living, a senior housing real estate investment trust that is set to debut Friday morning.Janus Living, a carve-out of medical REIT Healthpeak Properties, priced its initial public offering at $20 a share, the high end of its projected range. The company also upped the size of its stock sale, from 37 million shares to 42 million shares. Janus Living is raising $840 million from the IPO and would be valued at $5.1 billion at the $20 price. The stock will trade with the ticker symbol of JAN on the New York Stock Exchange.Investors love the big dividends. Healthpeak, which will still own more than 80% of Janus Living following the IPO, pays a dividend that yields nearly 7% for example.The performance of several of this year's deals so far is a relatively promising sign following a solid year for IPOs in 2025. And investors are eagerly awaiting more  deals ahead. Elon Musk's","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4225","8C8U.SI","CFA.SI","BK4007","BK4212","BOBS","BK4182","BK4585","OFRM","BK4203","FPS","WELL","BK4120","REIT","BK4178","JAN","BK6142","BK4588","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620590237","title":"Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620590237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620590237?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:00","pubTimestamp":1773831646,"startTime":"0","endTime":"0","summary":"Veradermics said three abstracts will be presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado, on March 27-31, 2026. Two social listening presentations are scheduled for March 27, 2026, at 11:25-11:30am MT and 2:15-2:20pm MT at the Colorado Convention Center.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6hRKb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":119,"code":"91000000","status":"200"}]}}